This study aimed to investigate the association between serum prolactin levels and psychiatric symptoms and cognitive function in drug-naïve schizophrenia patients. The study recruited 91 drug-naïve schizophrenia patients and 67 healthy controls. Sociodemographic and clinical data were collected, and cognitive function was assessed using the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB). Serum prolactin levels were measured, and statistical analyses were performed to examine the relationship between prolactin levels, clinical symptoms, and cognitive function. The study found that drug-naïve schizophrenia patients had severe cognitive deficits compared to healthy controls across all seven domains of the MCCB. However, no correlation was found between these patients’ serum prolactin levels and clinical severity or cognitive function. The drug-naïve schizophrenia patients had significant cognitive deficits compared to healthy controls. However, there was no significant relationship between prolactin levels and symptomatology and cognition in drug-naïve schizophrenia patients.

本研究旨在探讨初治精神分裂症患者血清催乳素水平与精神症状和认知功能之间的关联。该研究招募了 91 名未曾用药的精神分裂症患者和 67 名健康对照者。收集社会人口学和临床数据，并使用改善精神分裂症认知的测量和治疗研究 (MATRICS) 共识认知电池 (MCCB) 评估认知功能。测量血清催乳素水平，并进行统计分析以检查催乳素水平、临床症状和认知功能之间的关系。研究发现，与健康对照组相比，未接受过药物治疗的精神分裂症患者在 MCCB 的所有七个领域都存在严重的认知缺陷。然而，没有发现这些患者的血清催乳素水平与临床严重程度或认知功能之间存在相关性。与健康对照组相比，未接受过药物治疗的精神分裂症患者存在显着的认知缺陷。然而，在未接受药物治疗的精神分裂症患者中，催乳素水平与症状和认知之间没有显着关系。